Duvelisib (IPI-145, INK1197) , ≥98% , 1201438-56-3

CAS NO.：1201438-56-3

Empirical Formula: C22H17ClN6O

Molecular Weight: 416.86

MDL number: MFCD15144635

EINECS: 200-256-5

PRODUCT Properties

• Melting point: 205-206o C
• Boiling point: 757.8±60.0 °C(Predicted)
• Density: 1.474±0.06 g/cm3(Predicted)
• storage temp.: -20°C
• solubility: Soluble in DMSO (up to at least 25 mg/ml)
• form: White solid.
• pka: 10.05±0.10(Predicted)
• color: White
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
• InChI: InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1
• InChIKey: SJVQHLPISAIATJ-ZDUSSCGKSA-N
• SMILES: C1(=O)C2=C(C=CC=C2Cl)C=C([C@@H](NC2=C3C(=NC=N2)NC=N3)C)N1C1=CC=CC=C1

Description and Uses

Duvelisib (1201438-56-3) is a potent and selective (IC50’s: PI3Kα = 1602nM, PI3Kβ = 85nM, PI3Kδ= 2.5nM, PI3Kγ = 27nM) dual PI3Kδ/γ inhibitor.1 It inhibits B and T cell proliferation, blocks neutrophil migration, and inhibits basophil activation. Duvelisib antagonizes B-cell receptor cross-linking activated pro-survival signals in primary chronic lymphocytic leukemia cells.2?Duvelisib also shows preclinical/clinical activity against other hematologic malignancies such as Non-Hodgkins lymphoma, T-cell lymphoma, and others.3,4?Useful clinical agent for the treatment of various blood cancers. Low-dose treatment of T-cell-inflamed tumor models of head and neck cancers with Duvelisib enhanced responses to PD-L1 blockade via suppression of myeloid-derived suppressor cells.5?Higher doses reversed the effect due to suppression of tumor-infiltrating T lymphocytes

IPI 145 is an 1,2-dihydroisoquinolin-1(2H)-one derivative and has been developed as a modulator of PI3 kinase.

Safety

• Symbol(GHS): GHS08
• Signal word: Danger
• Hazard statements: H360